Teewinot Announces New Pharmaceutical Subsidiary

TAMPA, Fla., Oct. 9, 2018 /PRNewswire/ -- Today, Teewinot Life Sciences Corp., a global leader in the production of cannabinoid molecules, announces the launch of a new subsidiary, Canalis Pharmaceuticals, which will be led by Dr. Steve Orndorff as CEO.

Canalis is a drug discovery and development company that is using cannabinoids and their NCEs (New Chemical Entities) as small molecule libraries for identifying compounds with human therapeutic activity.  The company will be using in silico screening together with biological validation against drug targets to identify molecules with promising pharmacological properties.  Canalis will also use medicinal chemistry and advanced drug delivery technologies to optimize promising drug candidates for clinical development.  The Teewinot cannabinoid platform provides Canalis with a broad array of rare cannabinoids, prodrugs and other synthetic variants, and the ability to manufacture them at large scale in support of the Canalis clinical development program and eventual sale as prescription drugs.

Canalis has a worldwide exclusive license to the intellectual property of Teewinot Life Sciences for pharmaceutical applications.

Canalis will be announcing its Board of Directors and Scientific Advisory Board in the coming months that will include leaders in drug development from the biotech and pharmaceutical industries.

Dr. Steve Orndorff, a serial entrepreneur, will serve as the company's CEO. Dr. Orndorff has worked for over 30 years in drug development including pharmacogenomic therapies, orphan drugs, microbiome-based adjunctive therapies and novel drug manufacturing processes.  Earlier in his career he worked in protein engineering, recombinant protein expression systems, manufacturing process development and scale-up.  He holds a BS from Virginia Polytechnic Institute and State University, and a PhD from the University of Maryland.  In the past he was Chairman of the Colorado Institute for Drug, Device and Diagnostic Development, Chair and founding member of the Colorado BioScience Association, and President of the Society for Industrial Microbiology and Biotechnology.

"We are pleased to announce the spin out of Canalis Pharmaceuticals to serve the ever growing market demand surrounding cannabinoids," stated Teewinot Chairman, Charlie Brink. "The addition of Dr. Orndorff to our leadership team is creating a clear path for market leadership through the utilization of our proprietary intellectual property."

About Canalis Pharmaceuticals
Canalis Pharmaceuticals is a drug discovery and development subsidiary of Teewinot Life Sciences. Canalis works to investigate and develop human disease therapies through the use of cannabinoids. The company is focused on ethical drug development with reliable, scalable, biological production capability for cannabinoids. For more information, please visit www.canalispharma.com.  

About Teewinot Life Sciences Corporation
Teewinot Life Sciences, an international cannabinoid biotechnology company, has set out to revolutionize the cannabis market by becoming the leader in the use of patented biocatalytic and plant-based technologies that make the full spectrum of cannabinoids available in industrial quantities, in order to address therapeutic and wellness needs across all consumer sectors. For more information, please visit www.tlscorp.com or follow us on Twitter (@teewinot_corp).

For More Information:

Teewinot Life Sciences Corporation
Kelly Coughlin – Public Relations
(954) 294-9135


Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/teewinot-announces-new-pharmaceutical-subsidiary-300727295.html

SOURCE Teewinot Life Sciences Corporation


Back to news